MARKET

CRDF

CRDF

Cardiff Oncology Inc
NASDAQ
3.200
-0.050
-1.54%
After Hours: 3.290 +0.09 +2.81% 16:22 05/29 EDT
OPEN
3.250
PREV CLOSE
3.250
HIGH
3.280
LOW
3.090
VOLUME
251.53K
TURNOVER
0
52 WEEK HIGH
6.42
52 WEEK LOW
0.9400
MARKET CAP
143.12M
P/E (TTM)
-3.5520
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CRDF last week (0520-0524)?
Weekly Report · 2d ago
Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data
Cardiff Oncology's Onvansertib is a first-in-class oral PLK1 inhibitor that targets difficult-to-treat cancers. The company is a San Diego-based biotech focusing on developing innovative cancer treatments. Early data suggests OnvANSertib overcomes treatment resistance and improves response rates. Cardiff oncology is a biotech microcap with promising catalysts in 1H 2024. I deem CRDF a "speculative buy" for oncologists.
Seeking Alpha · 05/22 03:22
Weekly Report: what happened at CRDF last week (0513-0517)?
Weekly Report · 05/20 11:39
Weekly Report: what happened at CRDF last week (0506-0510)?
Weekly Report · 05/13 11:53
Weekly Report: what happened at CRDF last week (0429-0503)?
Weekly Report · 05/06 12:03
Cardiff Oncology Price Target Maintained With a $14.00/Share by HC Wainwright & Co.
Dow Jones · 05/06 10:38
HC Wainwright & Co. Reiterates Buy on Cardiff Oncology, Maintains $14 Price Target
Benzinga · 05/06 10:27
Buy Rating Affirmed on Cardiff Oncology as Phase 2 Trial Shows Promise for Accelerated Approval
TipRanks · 05/06 10:26
More
About CRDF
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has five ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, one trial (CRDF-001) in second-line treatment in patients with mPDAC, and three investigator-initiated trials in first line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.

Webull offers Cardiff Oncology Inc stock information, including NASDAQ: CRDF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRDF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRDF stock methods without spending real money on the virtual paper trading platform.